A. Barnadas

发表

Molecular predictors of response to chemotherapy in lung cancer.

J. Mate, E. Felip, A. Ariza, 2004, Seminars in oncology.

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Petra Seibold, Hubert Thierens, Alison M Dunning, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.

J B Vermorken, J. Garcia-conde, J. Baselga, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

B. Lloveras, I. Tusquets, M. Monzó, 2008, Clinical Cancer Research.

Author ' s response to reviews Title : Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential : a molecular and clinicopathological study Authors :

A. Barnadas, V. Llorente‐Cortés, D. Gonzalo-Calvo, 2022 .

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

C. Alonso, T. Ramón Y Cajal, M. Baiget, 2009, Breast Cancer Research and Treatment.

Triple-negative breast cancer

R. Rosell, M. Santarpia, S. Benlloch, 2012 .

Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin

V. Puntes, A. Barnadas, F. Romero, 2012, PloS one.

[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project].

A. Lluch, A. Llombart-Cussac, E. Alba, 2004, Medicina clinica.

Histologically invaded intramammary sentinel node, but no metastases found on axillary dissection.

A. Alastrué, A. Barnadas, M. Fraile, 1999, The European journal of surgery = Acta chirurgica.

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

C. Balañà, O. Gallego, M. Cuatrecasas, 2014, Journal of Neuro-Oncology.

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

C. Balañà, O. Gallego, M. Cuatrecasas, 2013, Journal of Neuro-Oncology.

Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).

M. Climent, L. Paz-Ares, J. Aparicio, 2002, European urology.

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

E. Lerma, E. Adrover, J. Sánchez-Payá, 2014, British Journal of Cancer.

TRAIL/Apo-2L death signaling pathway and molecular targeting agents: implications for chemoresistance

E. Felip, M. Monzó, M. Taron, 2001, Revista de Oncología.

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

E. Targarona, M. Baiget, A. Barnadas, 2011, International journal of radiation oncology, biology, physics.

PREOPERATIVE CHEMORADIOTHERAPY : POLYMORPHISMS IN THYMIDYLATE SYNTHASE , EPIDERMAL GROWTH FACTOR RECEPTOR , GSTP 1 , AND DNA REPAIR GENES

E. Targarona, M. Baiget, A. Barnadas, 2011 .

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

M. Piccart, M. Gnant, A. Goldhirsch, 2015, European journal of cancer.

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

I. Tusquets, A. Barnadas, E. Ciruelos, 2013, Clinical and Translational Oncology.

Molecular Detection of Peripheral Blood Breast Cancer mRNA Transcripts as a Surrogate Biomarker for Circulating Tumor Cells

M. Baiget, A. Lasa, A. Barnadas, 2013, PloS one.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant docetaxel for high-risk, node-negative breast cancer.

A. Ruíz, A. Lluch, J. Zaluski, 2010, The New England journal of medicine.

A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.

E. Felip, R. Rosell, M. Monzó, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma.

R. Mangues, A. Barnadas, F. Sancho, 2012, Carcinogenesis.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.

J. Mate, A. Ariza, R. Rosell, 1993, Oncogene.

Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

M. Baiget, A. Barnadas, D. Páez, 2014, Cancer letters.

Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil

J. Monill, M. Baiget, A. Barnadas, 2010, Journal of Cancer Research and Clinical Oncology.

Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?

M. Baiget, A. Barnadas, L. Paré, 2008, The Pharmacogenomics Journal.

Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles

S. Servitja, Ana Milena, A. Barnadas, 2012, Clinical and Translational Oncology.

Functions and workload of medical oncologists in Spain

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Exemestane versus anastrozole as front‐line endocrine therapy in postmenopausal patients with hormone receptor‐positive, advanced breast cancer

A. Ruíz, R. Andrés, A. Llombart-Cussac, 2012, Cancer.

Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review

J. Carles, R. Rosell, N. Ribelles, 1990, Journal of surgical oncology.

Time-to-progression in breast cancer: a stratification model for clinical trials.

A. Lluch, E. Alba, B. Munárriz, 2008, Breast.

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

B. Lloveras, I. Tusquets, M. Monzó, 2008, Clinical Cancer Research.

Circulating HER 2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer 1

B. Lloveras, A. Lluch, B. Massuti, 2000 .

Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity.

A. Alastrué, A. Barnadas, M Rull, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Internal Mammary Sentinel Node Metastases in an Otherwise Lymph‐Node Negative Breast Cancer Patient

A. Alastrué, A. Barnadas, M. Fraile, 2002, The breast journal.

False-negative rates in sentinel-node in breast cancer

A. Alastrué, A. Barnadas, M. Fraile, 1999, The Lancet.

Determinants of response and resistance to cytotoxics.

R. Rosell, M. Monzó, M. Taron, 2002, Seminars in oncology.

Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women.

T. Ramón Y Cajal, David Fisas, M. Baiget, 2011, Cancer epidemiology.

The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes

R. Mangues, A. Barnadas, M. Pavón, 2019, Head & neck.

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

E. Lerma, A. Barnadas, O. Bell, 2020, Frontiers in Oncology.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

J. Albanell, A. Lluch, L. Calvo, 2017, Clinical and Translational Oncology.

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

J. Garcia-conde, A. Lluch, V. Guillem, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity

A. Barnadas, D. Páez, P. Gallano, 2018, British journal of clinical pharmacology.

Relevance of CYP 3 A 4 * 20 , UGT 1 A 1 * 37 and UGT 1 A 1 * 28 variants in irinotecan-induced severe toxicity Running title : genetic biomarkers of irinotecan toxicity

A. Barnadas, D. Páez, P. Gallano, 2018 .

Final Results of the Randomized Phase II NorCap‐CA223 Trial Comparing First‐Line All‐Oral Versus Taxane‐Based Chemotherapy for HER2‐Negative Metastatic Breast Cancer

A. Barnadas, A. Chan, Michiel Botha, 2017, Clinical breast cancer.

Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

A. Barnadas, A. Feliu, M. Majem, 2011, Supportive Care in Cancer.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

J. Mayordomo, H. Burger, M. Marangolo, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

F. Rojo, A. Lluch, X. Bonfill, 2022, Clinical and Translational Oncology.

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period.

I. Gich, A. Barnadas, T. Hwang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

A. Kesselheim, I. Gich, A. Barnadas, 2020, Cancer.

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

R. Rosell, M. Taron, A. Abad, 2002, Lung cancer.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

M. Baiget, A. Barnadas, L. Paré, 2009, British Journal of Cancer.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

M. Baiget, A. Barnadas, L. Paré, 2008, British Journal of Cancer.

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.

M. Baiget, A. Barnadas, D. Páez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.

A. Barnadas, A. Ocaña, E. Amir, 2016, JAMA oncology.

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

H. Gómez, A. Guerrero-Zotano, A. Lluch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine-taxane experience in the treatment of metastatic breast cancer.

A. Barnadas, 2005, Cancer treatment reviews.

Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study

M. Margelí, N. Ribelles, M. Ramos, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor‐positive metastatic breast cancer: A confirmatory prospective study

J. Mayordomo, B. Lloveras, I. Tusquets, 2007, Cancer.

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

A. Lluch, X. Bonfill, S. Servitja, 2022, Clinical and Translational Oncology.

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

B. Lloveras, I. Tusquets, M. Monzó, 2005, Breast Cancer Research.

Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.

A. Lluch, V. Guillem, V. Carañana, 2000, Seminars in oncology.

Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients

A. Barnadas, M. Majem, A. Altés, 2019, Angiogenesis.

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

J. Carles, R. Rosell, A. Abad, 1992, Investigational New Drugs.

ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas

Enrique Lerma, E. Lerma, A. Barnadas, 2012, Journal of Cancer.

Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study

E. Lerma, L. Badimón, A. Barnadas, 2015, BMC Cancer.

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

J. Carles, B. Mellado, L. Paz-Ares, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Laminin and fibronectin expression during in vivo growth of embryoid bodies derived from teratocarcinoma

M. Monzó, A. Barnadas, D. Ruano, 2005, Virchows Archiv A.

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

E. Lerma, J. Prat, I. Aranda, 2008, Virchows Archiv.

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

E. Lerma, E. Adrover, A. Barnadas, 2012, British Journal of Cancer.

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.

G. Scagliotti, R. Rosell, A. Barnadas, 2003, Cancer control : journal of the Moffitt Cancer Center.

Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas.

E. Lerma, A. Barnadas, J. Muñoz, 2012, Human pathology.

Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.

R. Rosell, M. Monzó, A. Abad, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma

R. Mangues, A. Barnadas, M. Pavón, 2018, Head & neck.

Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients

R. Mangues, A. Barnadas, M. Pavón, 2015, Oncotarget.

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

R. Mangues, A. Barnadas, F. Sancho, 2008, International journal of cancer.

Genetic susceptibility associated with rare HRAS1 variable number of tandem repeats alleles in Spanish non-small cell lung cancer patients.

R. Rosell, M. Monzó, M. Guillot, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

H. Burger, M. Marangolo, M. Aapro, 2009, European journal of cancer.

Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

B. Lloveras, A. Lluch, B. Massuti, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Low-density lipoprotein receptor-related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas.

E. Lerma, A. Barnadas, A. Tibau, 2011, Human pathology.

MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer

E. Lerma, T. Ramón Y Cajal, A. Barnadas, 2020, Frontiers in Genetics.

KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

M. Baiget, A. Barnadas, D. Páez, 2017, Clinical and Translational Oncology.

SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients

M. Arranz, M. Baiget, A. Barnadas, 2017, Medical Oncology.

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

W. Reinhold, Y. Pommier, M. Esteller, 2015, Oncotarget.

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

J. Mayordomo, I. Tusquets, E. Alba, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

C. Perou, A. Picornell, H. Gómez, 2018, Clinical Cancer Research.

Current controversies in the management of early breast cancer

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

R. Rosell, M. Taron, A. Abad, 2003, Investigational New Drugs.

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.

J. Carles, R. Rosell, N. Ribelles, 1991, Oncology.

A phase II study of days 1 and 8 cisplatin and recombinant alpha‐2B interferon in advanced non‐small cell lung cancer

J. Carles, A. Ariza, R. Rosell, 1991, Cancer.

A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

J. Carles, R. Rosell, N. Ribelles, 1990, Cancer.

Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation

J. Suela, J. Cigudosa, C. Alonso, 2010, Breast Cancer Research and Treatment.

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti‐EGFR‐based therapy?

M. Baiget, I. Espinosa, A. Barnadas, 2010, Cancer science.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Arnoud J Templeton, C. Booth, A. Barnadas, 2018, Journal of the National Cancer Institute.

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007

A. Lluch, E. Alba, Á. Rodríguez-Lescure, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.

Philippe Bédard, F. Vera-Badillo, A. Barnadas, 2015, Journal of Clinical Oncology.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

J. Carles, L. Paz-Ares, J. Aparicio, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

E. Lerma, J. Prat, A. Barnadas, 2007, Modern Pathology.

Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study

I. Gich, A. Barnadas, M. Majem, 2021, International journal of cancer.

Treatment Response Evaluation: Science and Practice

I. Carrió, A. Barnadas, 2021, Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology.

I. Gich, A. Barnadas, R. García-Campelo, 2020, Frontiers in Oncology.

Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients

A. Barnadas, M. Majem, A. Altés, 2019, Angiogenesis.

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer12

E. Lerma, T. Ramón Y Cajal, I. Gich, 2014, Neoplasia.

Triple Negative Breast Carcinomas: Similarities and Differences With Basal Like Carcinomas

E. Lerma, J. Prat, A. Barnadas, 2009, Applied immunohistochemistry & molecular morphology : AIMM.

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

S. González, I. Tusquets, A. Barnadas, 2009, British Journal of Cancer.

Neoadjuvant endocrine therapy for breast cancer: past, present and future

L. Calvo, A. Barnadas, P. Sánchez‐Rovira, 2008, Anti-cancer drugs.

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

A. Barnadas, M. A. Ortiz, S. Vidal, 2021, Cancer Immunology, Immunotherapy.

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study

J. Palacios, J. Ramírez, E. Carrasco, 2012, Clinical and Translational Oncology.

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

O. Gallego, A. Barnadas, D. Páez, 2018 .

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.

J. Carles, R. Rosell, A. Abad, 1992, European journal of cancer.

Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.

A. Barnadas, J. Jimeno, E. Díaz-Rubio, 1997, European journal of cancer.

CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced‐stage head and neck squamous cell carcinoma

R. Mangues, A. Barnadas, M. Pavón, 2016, Head & neck.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

F. Rojo, E. Espinosa, J. Palacios, 2017, The oncologist.

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

F. Rojo, J. Albanell, A. Lluch, 2014, British Journal of Cancer.

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5,456 breast and prostate cancer patients

Sydes, H. Ostrer, J. Chang-Claude, 2017 .

ATM rs1801516 SNP and toxicity after radiotherapy

Sydes, H. Ostrer, J. Chang-Claude, 2017 .

Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study

M. Margelí, A. Barnadas, M. Fraile, 2011, BMC Cancer.

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

A. Tres, E. Alba, M. Martín, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

R. Rosell, M. Taron, M. Margelí, 2010, PloS one.

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

S. Servitja, M. Margelí, S. Morales, 2018, Clinical and Translational Oncology.

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

E. Alba, M. Ramos, Miguel Martín, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy

P. Martínez, M. Provencio, A. Barnadas, 1999, Cancer Chemotherapy and Pharmacology.

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

Á. Rodríguez-Lescure, A. Barnadas, P. Sánchez‐Rovira, 2011, Advances in therapy.

HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy

R. Rosell, M. Margelí, B. Cirauqui, 2017 .

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.

J. Carles, A. Ariza, R. Rosell, 1993, Lung cancer.

Current controversies in the management of breast cancer

J. Albanell, A. Lluch, P. Gascón, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Doxorubicin and paclitaxel in advanced breast carcinoma

A. Lluch, B. Massuti, A. Barnadas, 2000, Cancer.

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer

A. Barnadas, A. Ocaña, E. Amir, 2018, Oncotarget.

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

R. Rosell, A. Abad, N. Ribelles, 1992, Investigational New Drugs.

Neoadjuvant treatment in young women with breast cancer

A. Barnadas, 2010, Breast Cancer Research and Treatment.

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study

J. Maurel, C. Pericay, A. Barnadas, 2013, Investigational New Drugs.

Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain

J. Borrás, J. Espinàs, A. Barnadas, 2019, Breast Cancer Research and Treatment.

BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG)

J. Tabernero, J. Aparicio, E. Alba, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).

A. Llombart-Cussac, S. Morales, A. Barnadas, 2010 .

Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis

E. Lerma, A. Barnadas, A. Gallardo, 2017, Breast Cancer Research and Treatment.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

C. Perou, K. Hoadley, A. Picornell, 2018, Clinical Cancer Research.

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.

A. Barnadas, J. Capdevila, C. Pallarés, 2007, Lung cancer.

Sequential Combination of Methotrexate (MTX), 5‐Fluorouracil (FU), and High‐Dose Folinic Acid (FA) in Advanced Colorectal Cancer: Double Biochemical Modulation?

J. Carles, R. Rosell, A. Abad, 1991, American journal of clinical oncology.

Sequential methotrexate, 5‐fluorouracil (5‐FU), and high dose leucovorin versus 5‐FU and high dose leucovorin versus 5‐FU alone for advanced colorectal cancer. A multi‐institutional randomized trial

R. Rosell, A. Abad, A. Font, 1995, Cancer.

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

A. Barnadas, D. Páez, L. Cirera, 2018, British Journal of Cancer.

EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer

E. Targarona, M. Baiget, A. Barnadas, 2014, The Pharmacogenomics Journal.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

A. Lluch, S. González, R. Andrés, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential combination chemotherapy for malignant germ cell tumors of the ovary

A. Barnadas, J. Germà, J. Badia, 1988, Cancer.

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

S. González, M. Margelí, E. Carrasco, 2019, Journal of Patient-Reported Outcomes.

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan

M. Baiget, A. Lasa, A. Barnadas, 2013, The Pharmacogenomics Journal.

Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort?

N. Montserrat, E. Lerma, J. Prat, 2011, Human pathology.

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

P. Villagrasa, S. Morales, A. Barnadas, 2021, Frontiers in Oncology.

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

H. Rugo, M. Campone, O. Petrenciuc, 2017 .

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.

J. Carles, R. Rosell, A. Abad, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

J. Albanell, A. Lluch, A. de Juan, 2019, Journal of drug assessment.

Mammographic density and breast cancer in women from high risk families

Marina Pollán, Joan Brunet, Judith Balmaña, 2015, Breast Cancer Research.

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients

M. Baiget, A. Barnadas, N. Sala, 2013, Pharmacogenetics and genomics.

Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study

E. Lerma, L. Badimón, A. Barnadas, 2015, BMC Cancer.

Abstract P2-01-06: Association between Circulating Tumor Cells and Bone Turnover Markers in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study)

I. Tusquets, M. Margelí, L. Calvo, 2012 .

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

M. Margelí, A. Barnadas, J. M. Vega, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[Analysis of telomeric length in epithelial carcinoma of the ovary].

R. Rosell, M. Monzó, A. Barnadas, 1998, Medicina clinica.

Lung cancer and cigarette smoking in women: A case‐control study in barcelona (Spain)

A. Agudo, A. Barnadas, J. Planas, 1994, International journal of cancer.

Anti‐Ri‐associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer

A. Barnadas, F. Graus, M. Codina, 1993, Neurology.

High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma

R. Mangues, A. Barnadas, M. Pavón, 2013, Cancer medicine.

Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy

M. Baiget, A. Barnadas, D. Páez, 2015, The Pharmacogenomics Journal.

Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial.

I. Tusquets, M. Margelí, A. Barnadas, 2004, Journal of Clinical Oncology.